Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

LICENSE AGREEMENTS (Details)

LICENSE AGREEMENTS (Details) - USD ($) $ in Millions	1 Months Ended				6 Months Ended
LICENSE AGREEMENTS (Details) - USD ($) $ in Millions	Feb. 28, 2023	Jan. 31, 2022	Dec. 31, 2020	Aug. 31, 2017	Dec. 31, 2023
XOMA (US) LLC \| Xoma License Agreement \| Upon Clinical and Regulatory Milestones \| Maximum
License Agreements
Maximum amount of milestone events		$ 35.0
XOMA (US) LLC \| Xoma License Agreement \| After Clinical and Regulatory Milestones \| Maximum
License Agreements
Maximum amount of milestone events		185.0
XOMA (US) LLC \| Phase 2 Clinical Trial RZ358 \| Xoma License Agreement
License Agreements
Milestone closing payment		2.0
XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 \| Xoma License Agreement \| Scenario, Upon First Dosing Of The First Patient [Member]
License Agreements
Milestone closing payment		$ 5.0			$ 5.0
XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 \| Xoma License Agreement \| Scenario, Upon Dosing Of The Last Patient [Member]
License Agreements
Milestone closing payment					$ 5.0
ActiveSite Pharmaceuticals, Inc
License Agreements
Royalties percentage				2.00%
ActiveSite Pharmaceuticals, Inc \| Development And License Agreement
License Agreements
Milestone closing payment			$ 1.0
ActiveSite Pharmaceuticals, Inc \| Development And License Agreement \| Plan \| Maximum
License Agreements
Maximum amount of milestone events				$ 46.5
ActiveSite Pharmaceuticals, Inc \| Phase 2 Clinical Trial RZ402 \| Development And License Agreement
License Agreements
Milestone closing payment	$ 3.0
ActiveSite Pharmaceuticals, Inc \| Phase 3 Clinical Trial RZ 402 \| Development And License Agreement \| Scenario, Upon First Dosing Of The First Patient [Member]
License Agreements
Milestone closing payment				$ 5.0